

ASX Announcement

Medibio Limited – 15 February 2021



Underwritten Share Purchase Plan Update

Melbourne, Australia and Minneapolis, MN – 15 February 2021: Medibio Limited (“MEB” or “Medibio”)(ASX: MEB)(OTCPINK: MDBIF) is pleased to announce the following update in relation to its Share Purchase Plan (SPP), further to the announcement by the Company on 10 February 2021.

An Underwriting Agreement for the SPP has been executed with CPS Capital Group Pty Ltd (CPS), pursuant to which the SPP will be fully underwritten for the full Offer of \$500,000. In consideration for the underwriting CPS will receive an underwriting fee of A\$20,000 in addition to a 4% fee for the underwriting up to a maximum amount of \$500,000.

The Company does not at this stage anticipate any changes to the timetable previously advised via the Announcement on 10 February 2021.

– ENDS –

This announcement is authorised for release to the market by the Board of Directors of Medibio Limited.

About Medibio Limited

Medibio (ASX: MEB) (OTCPINK: MDBIF) is a health technology company pioneering the use of objective measures to aid in the early detection and screening of mental health conditions. Through their Corporate Health product, the Company offers mental well-being solutions for businesses and are also developing products to serve the healthcare provider market. The company was founded in Australia, with offices located in Melbourne (Vic) and U.S. offices in Minneapolis, MN. Medibio is listed on the Australian Securities Exchange Ltd and trades on the OTC Pink Open Market. Investors can find additional information on www.otcmarkets.com and www.asx.com.au.

Medibio Investor and Media Enquiries:

Arthur Chan

WE Communications

T: +61 (0) 404 369 388

WE-AUMedibio@we-worldwide.com